PCSK9 and angina pectoris: A number of large-scale, long-term randomized controlled trials (Table 5) demonstrated that intensive reductions in levels of LDL-C using high-dose statins, PCSK9 inhibitors, or bempedoic acid significantly reduced the risk of first-onset or recurrent MACEs, which were generally referred to as the composite of cardiovascular death, non-fatal MI, non-fatal stroke, unstable angina, or coronary revascularization (32, 42–50).